Key Regulatory Elements of the TGFbeta-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types
Storey, C. M.; Cheng, M.; Altai, M.; Park, J. E.; Tran, J.; Lueong, S. S.; Thorek, D. L.; Mao, L.; Zedan, W.; Yuen, C.; Ridley, A.; Trajkovic-Arsic, M.; Herrmann, K.; Subudhi, S. K.; Siddiqui, B. A.; Lueckerath, K.; Siveke, J.; Damoiseaux, R.; Yang, X.; Ulmert, D.
Show abstract
Transforming growth factor-beta (TGF{beta}) has dual roles in cancer, initially suppressing tumors but later promoting metastasis and immune evasion. Efforts to inhibit TGF{beta} have been largely unsuccessful due to significant toxicity and indiscriminate immunosuppression. Leucine-rich repeat-containing protein 15 (LRRC15) is a TGF{beta}-regulated antigen expressed by mesenchymal-derived cancer cells and cancer-associated fibroblasts (CAFs). In preclinical studies, ablation of TGF{beta}-driven LRRC15+ CAFs increased tumor infiltration of CD8+ T cells. However, the underlying pathobiological mechanisms prompting TGF{beta}s upregulation of LRRC15 expression are unclear. Using an integrated approach combining functional compound screening with single-cell RNA sequencing, we reveal key genomic features regulating TGF{beta}s ability to increase LRRC15 expression on cancer cells. Construction of gene regulatory networks converged our analyses on four key genes--MMP2, SPARC, TGF{beta}R2, and WNT5B--central to TGF{beta}-induced LRRC15 pathobiology. Validation of these genes in cell models and their use in predicting immunotherapy responses highlight their potential in refining immunotherapy strategies and personalizing co-treatment options.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer 95%
- Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity 93%
- Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors 93%
Similar papers in this journal
Similar papers in this journal
- Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics 95%
- EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas 94%
- A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC 94%
Similar papers in this journal
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 96%
- Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction 96%
- Transcriptional pattern enriched for synaptic signaling is associated with shorter survival of patients with high-grade serous ovarian cancer 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.